Relation of Cardiac Dysfunction to Thyroid Stimulating Hormone in Children with Down Syndrome

2017 ◽  
Vol 34 (3-4) ◽  
pp. 145-156
Author(s):  
Mohamed E. Mowafy ◽  
Omneya I. Youssef ◽  
Heba S. Abd Elkhalek
Keyword(s):  
Down Syndrome ◽  
Cardiac Dysfunction ◽  
Thyroid Stimulating Hormone ◽  
Children With Down Syndrome ◽  
Stimulating Hormone

Thyroid stimulating hormone — Receptor overexpression in brain of patients with Down Syndrome and Alzheimer's disease

Life Sciences ◽  
1999 ◽  
Vol 64 (12) ◽  
pp. 1037-1044 ◽  
Author(s):  
Olga Labudova ◽  
Nigel Cairns ◽  
Thomas Koeck ◽  
Erwin Kitzmueller ◽  
Hermann Rink ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Down Syndrome ◽  
Hormone Receptor ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

scholarly journals Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Verónica Vidal ◽  
Alba Puente ◽  
Susana García-Cerro ◽  
María Teresa García Unzueta ◽  
Noemí Rueda ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Down Syndrome ◽  
Open Field ◽  
Morris Water Maze ◽  
Water Maze ◽  
Thyroid Stimulating Hormone ◽  
Hormone Levels ◽  
Hole Board ◽  
Stimulating Hormone

All individuals with Down syndrome (DS) eventually develop Alzheimer’s disease (AD) neuropathology, including neurodegeneration, increases in β-amyloid (Aβ) expression, and aggregation and neurofibrillary tangles, between the third and fourth decade of their lives. There is currently no effective treatment to prevent AD neuropathology and the associated cognitive degeneration in DS patients. Due to evidence that the accumulation of Aβ aggregates in the brain produces the neurodegenerative cascade characteristic of AD, many strategies which promote the clearance of Aβ peptides have been assessed as potential therapeutics for this disease. Bexarotene, a member of a subclass of retinoids that selectively activates retinoid receptors, modulates several pathways essential for cognitive performance and Aβ clearance. Consequently, bexarotene might be a good candidate to treat AD-associated neuropathology. However, the effects of bexarotene treatment in AD remain controversial. In the present study, we aimed to elucidate whether chronic bexarotene treatment administered to the most commonly used murine model of DS, the Ts65Dn (TS) mouse could reduce Aβ expression in their brains and improve their cognitive abilities. Chronic administration of bexarotene to aged TS mice and their CO littermates for 9 weeks diminished the reference, working, and spatial learning and memory of TS mice, and the spatial memory of CO mice in the Morris water maze. This treatment also produced marked hypoactivity in the plus maze, open field, and hole board tests in TS mice, and in the open field and hole board tests in CO mice. Administration of bexarotene reduced the expression of Aβ1-40, but not of Aβ1-42, in the hippocampi of TS mice. Finally, bexarotene increased Thyroid-stimulating hormone levels in TS mice and reduced Thyroid-stimulating hormone levels in CO mice, while animals of both karyotypes displayed reduced thyroxine levels after bexarotene administration. The bexarotene-induced hypothyroidism could be responsible for the hypoactivity of TS and CO mice and their diminished performance in the Morris water maze. Together, these results do not provide support for the use of bexarotene as a potential treatment of AD neuropathology in the DS population.

First-trimester maternal serum human thyroid-stimulating hormone in chromosomally normal and Down syndrome pregnancies

2001 ◽  
Vol 21 (9) ◽  
pp. 723-725 ◽  
Author(s):  
Martin J. N. Weinans ◽  
John J. Pratt ◽  
Ben T. H. M. de Wolf ◽  
Albert Mantingh
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Thyroid Stimulating Hormone ◽  
Maternal Serum ◽  
Human Thyroid ◽  
Stimulating Hormone

Screening for Hypothyroidism in Down Syndrome Using the Capillary Thyroid Stimulating Hormone Method

2015 ◽  
Vol 166 (4) ◽  
pp. 1013-1017.e2 ◽  
Author(s):  
Sheena McGowan ◽  
Jeremy Jones ◽  
Donald McMillan ◽  
Kirsty McLaughlin ◽  
Sarah Smith ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document